DE69129990D1 - Modifizierter menschlicher tumornekrosisfaktor-alpha-rezeptor - Google Patents

Modifizierter menschlicher tumornekrosisfaktor-alpha-rezeptor

Info

Publication number
DE69129990D1
DE69129990D1 DE69129990T DE69129990T DE69129990D1 DE 69129990 D1 DE69129990 D1 DE 69129990D1 DE 69129990 T DE69129990 T DE 69129990T DE 69129990 T DE69129990 T DE 69129990T DE 69129990 D1 DE69129990 D1 DE 69129990D1
Authority
DE
Germany
Prior art keywords
pct
tnf alpha
necrosis factor
tumor necrosis
human tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69129990T
Other languages
English (en)
Other versions
DE69129990T2 (de
DE69129990T3 (de
Inventor
Marc The Charing Cros Feldmann
Patrick Gray
Martin Turner
Fionula Brennan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kennedy Trust for Rheumatology Research
Original Assignee
MATHILDA AND TERENCE KENNEDY INSTITUTE OF RHEUMATOLOGY LONDON GB
Kennedy Institute of Rheumotology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10683931&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69129990(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by MATHILDA AND TERENCE KENNEDY INSTITUTE OF RHEUMATOLOGY LONDON GB, Kennedy Institute of Rheumotology filed Critical MATHILDA AND TERENCE KENNEDY INSTITUTE OF RHEUMATOLOGY LONDON GB
Publication of DE69129990D1 publication Critical patent/DE69129990D1/de
Publication of DE69129990T2 publication Critical patent/DE69129990T2/de
Application granted granted Critical
Publication of DE69129990T3 publication Critical patent/DE69129990T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69129990T 1990-10-18 1991-10-18 Modifizierter menschlicher tumornekrosisfaktor-alpha-rezeptor Expired - Lifetime DE69129990T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9022648 1990-10-18
GB909022648A GB9022648D0 (en) 1990-10-18 1990-10-18 Polypeptide and its use
PCT/GB1991/001826 WO1992007076A1 (en) 1990-10-18 1991-10-18 Modified human tnfalpha (tumor necrosis factor alpha) receptor

Publications (3)

Publication Number Publication Date
DE69129990D1 true DE69129990D1 (de) 1998-09-17
DE69129990T2 DE69129990T2 (de) 1998-12-24
DE69129990T3 DE69129990T3 (de) 2006-07-13

Family

ID=10683931

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69129990T Expired - Lifetime DE69129990T3 (de) 1990-10-18 1991-10-18 Modifizierter menschlicher tumornekrosisfaktor-alpha-rezeptor

Country Status (9)

Country Link
US (2) US5633145A (de)
EP (1) EP0556207B2 (de)
JP (1) JPH06504192A (de)
AT (1) ATE169675T1 (de)
DE (1) DE69129990T3 (de)
DK (1) DK0556207T4 (de)
ES (1) ES2121789T5 (de)
GB (1) GB9022648D0 (de)
WO (1) WO1992007076A1 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512544A (en) * 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
DE59010941D1 (de) 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US7264944B1 (en) * 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
DK0417563T3 (da) 1989-09-12 2000-11-06 Hoffmann La Roche TNF-bindende proteiner
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
EP1239043A3 (de) * 1992-03-30 2003-01-02 Immunex Corporation Fusionsproteine enthaltend Tumor Necrosis Factor-Rezeptor
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US7070783B1 (en) 1995-05-09 2006-07-04 The Mathilda And Terence Kennedy Institute Of Rheumatology Small molecular weight TNF receptor multimeric molecule
EP1500702A1 (de) * 1996-04-01 2005-01-26 Genentech, Inc. APO-2LI and APO-3 Apoptosis Polypeptides aus der TNFR1 Familie
US20020165157A1 (en) * 1996-04-01 2002-11-07 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
EP0942740B1 (de) 1996-12-06 2003-08-27 Amgen Inc., Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000061610A2 (en) * 1999-04-12 2000-10-19 Agensys, Inc. Prostate-restricted gene 30p3c8 expressed in prostate cancer
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
EP1939300A1 (de) 1999-05-28 2008-07-02 Targeted Genetics Corporation Verfahren und Zusammensetzung zur Senkung des Spiegels des Tumornekrosefaktors (TNF) bei TNF-assoziierten Leiden
PT1180159E (pt) * 1999-05-28 2008-12-05 Targeted Genetics Corp Métodos e composições para abaixamento do nível de factor de necrose tumoral (tnf) nos distúrbios associados a tnf
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
EP1263788A2 (de) 2000-02-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identifizierung einer domäne in der familie der tumornekrose-faktor rezeptoren, die die anordnung des rezeptors vor der ligandbindung und sein funktion vermittelt
AU4541101A (en) 2000-03-02 2001-09-12 Xencor Inc Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
MEP32608A (en) 2001-06-26 2011-02-10 Amgen Fremont Inc Antibodies to opgl
EP1414517A4 (de) * 2001-06-26 2008-02-06 Photomed Technologies Inc Mehrfach-wellenlängen-illuminator
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US7425331B2 (en) * 2002-04-10 2008-09-16 Protalex, Inc. Protein A methods of use
US7211258B2 (en) * 2002-04-10 2007-05-01 Protalex, Inc. Protein A compositions and methods of use
EP1545608A4 (de) 2002-06-28 2006-09-13 Centocor Inc Ch1-deletierte säugetier-mimetikörper, zusammensetzungen, verfahren und anwendungen
US7285269B2 (en) * 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
WO2004060911A2 (en) * 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
EP1631266B1 (de) 2003-05-13 2011-03-16 DePuy Spine, Inc. Verfahren zur behandlung von degenerativer bandscheibenerkrankung
US7553827B2 (en) 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US7344716B2 (en) 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
US8361467B2 (en) 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
EP1691776A4 (de) * 2003-12-10 2009-07-15 Advanced Biotherapy Inc Behandlung von aids
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
US20100041596A1 (en) * 2005-06-24 2010-02-18 Michael Lenardo Amelioration of Inflammatory Arthritis By Targeting the Pre-ligand Assembly Domain (Plad) of Tumor Necrosis Factor Receptors
EP1896073B1 (de) 2005-06-30 2013-03-06 Janssen Biotech, Inc. Anti-il-23-antikörper, zusammensetzungen, verfahren und verwendung
US7785834B2 (en) * 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
WO2007058894A2 (en) * 2005-11-10 2007-05-24 The University Of North Carolina At Chapel Hill Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
RS55963B1 (sr) 2005-12-29 2017-09-29 Janssen Biotech Inc Humana anti-il-23 antitela, kompozicije, metode i upotrebe
AU2006344750A1 (en) * 2006-06-15 2007-12-27 Targeted Genetics Corporation Methods for treating target joints in inflammatory arthritis using AAV vectors encoding a TNF antagonist
EP2851064A3 (de) 2006-07-11 2015-08-05 Roy C. Levitt Prävention und Therapie von Rhinosinusitis mit proinflammatorischen Zytokinhemmern
LT2068889T (lt) 2006-08-10 2020-02-10 Roy C. Levitt Anakinra, naudojama bronchiolito obliteranso sindromo gydymui
US20090264353A1 (en) * 2007-10-19 2009-10-22 Santaris Pharma A/S Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
US8986696B2 (en) 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
AU2009281713B9 (en) 2008-08-14 2014-05-29 Teva Pharmaceuticals Australia Pty Ltd Anti-IL-12/IL-23 antibodies
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
WO2011049350A2 (ko) * 2009-10-19 2011-04-28 한올바이오파마주식회사 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법
EP2507267B1 (de) * 2009-12-02 2016-09-14 Acceleron Pharma, Inc. Zusammensetzungen und verfahren zur erhöhung der serumshaltbarkeit von fc-fusionsproteinen
US20110187776A1 (en) * 2010-02-01 2011-08-04 Poly-America, L.P. Multiple Inkjet Cannon Printing System
EP2718328A4 (de) 2011-06-08 2014-12-24 Acceleron Pharma Inc Zusammensetzungen und verfahren zur erhöhung der halbwertszeit von serum
US9764000B2 (en) * 2012-03-14 2017-09-19 Levicept Ltd Therapeutic use of p75NTR neurotrophin binding protein
GB201316592D0 (en) 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
GB201412748D0 (en) 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
GB201504691D0 (en) 2015-03-19 2015-05-06 Levicept Ltd Fusion protein
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
CN110234351A (zh) 2017-01-30 2019-09-13 詹森生物科技公司 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
WO2018147915A1 (en) 2017-02-07 2018-08-16 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
EP3911676A1 (de) 2019-01-15 2021-11-24 Janssen Biotech, Inc. Anti-tnf-antikörperzusammensetzungen und verfahren zur behandlung von juveniler idiopathischer arthritis
KR20210118878A (ko) 2019-01-23 2021-10-01 얀센 바이오테크 인코포레이티드 건선성 관절염의 치료 방법에 사용하기 위한 항-tnf 항체 조성물
WO2020183271A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
KR20210142002A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물을 생성하기 위한 제조 방법
WO2020183270A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
KR20220012883A (ko) 2019-05-23 2022-02-04 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용요법으로 염증성 장질환을 치료하는 방법
KR20220030952A (ko) 2019-06-03 2022-03-11 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
MX2021014885A (es) 2019-06-03 2022-04-06 Janssen Biotech Inc Composiciones de anticuerpos anti-tnf, y métodos para el tratamiento de la artritis psoriásica.
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
AU2022308201A1 (en) 2021-07-09 2024-02-22 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
CN118139883A (zh) 2021-07-09 2024-06-04 詹森生物科技公司 用于生产抗tnf抗体组合物的制造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
DE59010941D1 (de) * 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs

Also Published As

Publication number Publication date
WO1992007076A1 (en) 1992-04-30
DK0556207T3 (da) 1999-05-17
ES2121789T3 (es) 1998-12-16
EP0556207B1 (de) 1998-08-12
GB9022648D0 (en) 1990-11-28
JPH06504192A (ja) 1994-05-19
ES2121789T5 (es) 2006-05-01
EP0556207A1 (de) 1993-08-25
ATE169675T1 (de) 1998-08-15
DE69129990T2 (de) 1998-12-24
US5863786A (en) 1999-01-26
US5633145A (en) 1997-05-27
EP0556207B2 (de) 2005-11-16
DK0556207T4 (da) 2006-02-27
DE69129990T3 (de) 2006-07-13

Similar Documents

Publication Publication Date Title
DE69129990D1 (de) Modifizierter menschlicher tumornekrosisfaktor-alpha-rezeptor
ATE314479T1 (de) Aktivierung von rezeptoren fähig zur oligomerisierung durch verwendung von fusionierten rezeptor liganden
ATE290595T1 (de) Gamma-heregulin
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ATE486937T1 (de) Chimärische heteromultimerische adhesine
ATE296799T1 (de) P38-inhibitoren
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
DE69839340D1 (de) Mutanten DES VASKULÄREN, ENDOTHELZELLEN-SPEZIFISCHEN WACHSTUMSFAKTORS C (VEGF-C) UND DEREN VERWENDUNGEN
EA199900559A1 (ru) Замещенные, азотсодержащие гетероциклы в качестве ингибиторов протеинкиназы p38
DE69434538D1 (de) Vaskularer endothelialer wachstumsfaktor 2
DK14587A (da) Anvendelse af specifikke n-methyl-d-aspartat-receptorantagonister til undgaaelse af og behandling af neurodegeneration
DK0592521T3 (da) Marv-afledte humane mesenchymal-stamceller og monoklonale antistoffer specifikke for nævnte celler
ATE395081T1 (de) Lo-cd2a antikörper und dessen verwendungen zur hemmung von t-zell aktivierung und wachstum
DE3650647D1 (de) Arzneimittel zur Behandlung von Anxietas
DK0613499T4 (da) Humane IT-4-mutantproteiner
NO910232D0 (no) Anordning ved stol.
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
DK1283217T3 (da) Antistoffer mod IL-8-receptoren og deres terapeutiske anvendelser
ATE190839T1 (de) Verwendung von prodelphidinen zur behandlung von arthrose
ATE182467T1 (de) Verwendung von antagonisten oder partiellen agonisten am 5-ht 1a-rezeptor zur behandlung und prävention von kognitiven störungen
ATE181668T1 (de) Verwendung von 5-ht4 rezeptorantagonisten zur behandlung von vorhof-fibrillation und zur vorbeugung von schlaganfall
DE69133390D1 (de) Verwendung von angiotensin-ii-rezeptorantagonisten in der behandlung von hämorragischem schlaganfall
ATE432080T1 (de) Lo-cd2a antikörper und deren verwendung zur hemmung der t-zellen aktivierung und proliferation
ATE302273T1 (de) Cadherin derived growth factor und seine verwendung
GR1002381B (el) Ουσιες σχετιζομενες με συμπληρωματικα πεπτιδια των νεκρωτικων παραγοντων ογκων h του r55-υποδοχεα του νεκρωτικου παραγοντα ογκων.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: SYNOVIS LTD., LONDON, GB

8327 Change in the person/name/address of the patent owner

Owner name: THE MATHILDA AND TERENCE KENNEDY INSTITUTE OF , GB